Hoodia gordonii (Masson) Sweet ex Decaisne

2021 ◽  
Vol 42 (05) ◽  
pp. 267-274
Author(s):  
Klaus Peter Latté
Keyword(s):  
Intellectual Property ◽  
Property Rights ◽  
Intellectual Property Rights ◽  
Klinische Studie ◽  
Benefit Sharing ◽  
Hoodia Gordonii

Zusammenfassung Hoodia gordonii wird seit Langem von den indigenen Einwohnern des südlichen Afrikas, den Khoisan, zur Stillung des Hungers und des Durstes während langer Jagdreisen angewendet. Zahlreiche seltene Steroidglykoside wurden isoliert, u.a. auch die Substanz „P57“, die als wirksamer Stoff angesehen wurde. Einige Wirkmechanismen wurden für die Steroidglykoside und für Extrakte beschrieben, die die appetitunterdrückende Wirkung belegen. Ausgehend von diesem Wissen wurden von internationalen Firmen in den 1990er und 2000er Jahren Produkte mit H. gordonii bzw. „P57“ zur Gewichtsreduktion bei Übergewicht entwickelt. Nur eine klinische Studie ist jedoch in voller Länge veröffentlicht, in der eine Gewichtsreduktion bei Übergewicht nicht bestätigt werden konnte. Die Nutzung und Vermarktung dieser Pflanze war aufgrund von Fragen zu den „intellectual property rights“ und zum sog. „benefit sharing“ sehr umstritten.

scholarly journals Pelindungan Hak Paten atas Pengetahuan Obat Tradisional Melalui Pasal 26 UU No. 13 Tahun 2016 tentang Paten (Protection of Patent Rights on Traditional Medicine Knowledge Through Article 26 of Law No. 13 of 2016 Concerning Patents)

2019 ◽  
Vol 10 (1) ◽  
pp. 49-65
Author(s):  
Trias Palupi Kurnianingrum
Keyword(s):  
Intellectual Property ◽  
Property Rights ◽  
Traditional Medicine ◽  
Traditional Knowledge ◽  
Intellectual Property Rights ◽  
Trips Agreement ◽  
Patent Law ◽  
Benefit Sharing ◽  
Traditional Medicines ◽  
Patent Rights

Patent as a branch of Intellectual Property Rights (IPR) serves to protect inventions on the field of technology, one of them being medicine. The rise on the number of cases on the theft of genetic resources and traditional knowledge on the field of medicine for commercialization purposes shows that the protection of patent rights on traditional medicine knowledge is still not optimal. This article is the result of a normative juridical research which is supported by an empirical data, examines the protection of patent rights on traditional medicine knowledge and the implementation of Article 26 of Law No. 13 of 2016 on Patents (Patent Law year 2016). In the research results, it was mentioned that even though the TRIPs Agreement did not accommodate the traditional knowledge, the presence of Patent Law year 2016 complemented the Indonesian government's efforts to save the knowledge of traditional medicines from biopiracy and misappropriation. It is necessary to regulate the disclosure obligation in TRIPs agreement and further mechanism regarding benefit sharing and granting access to traditional medicines knowledge. AbstrakPaten merupakan salah satu cabang Hak Kekayaan Intelektual yang berfungsi untuk melindungi invensi di bidang teknologi, salah satunya obat-obatan. Maraknya kasus pencurian sumber daya genetik dan pengetahuan tradisional di bidang obat-obatan untuk tujuan komersialisasi menunjukkan bahwa pelindungan hak paten atas pengetahuan obat tradisional masih belum maksimal. Artikel ini merupakan hasil penelitian yuridis normatif yang didukung dengan data empiris, membahas mengenai pelindungan hak paten atas pengetahuan obat tradisional dan implementasi Pasal 26 Undang-Undang Nomor 13 Tahun 2016 tentang Paten (UU Paten 2016). Di dalam hasil penelitian, disebutkan meskipun Perjanjian Trade-Related Aspects of Intellectual Property Rights (TRIPs) belum mengakomodasi pengetahuan tradisional namun hadirnya UU Paten 2016 melengkapi usaha pemerintah Indonesia dalam menyelamatkan pengetahuan obat tradisional dari biopiracy dan misappropriation. Perlu pengaturan kewajiban disclosure di dalam Perjanjian TRIPs dan mekanisme lebih lanjut mengenai benefit sharing dan pemberian akses atas pengetahuan obat tradisional.

Africa and Intellectual Property Rights for Plant Varieties

2020 ◽  
Author(s):  
Titilayo Adebola
Keyword(s):  
Intellectual Property ◽  
Property Rights ◽  
Intellectual Property Rights ◽  
African Country ◽  
Biological Diversity ◽  
Plant Genetic Resources ◽  
Benefit Sharing ◽  
Small Scale ◽  
Model Law ◽  
Plant Breeders Rights

The entry into force of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) on 1 January 1995 reversed Africa’s relationship with intellectual property rights for Plant Varieties. Except for Kenya, South Africa, and Zimbabwe, no other African country had intellectual property rights systems for plant varieties before TRIPS. However, the obligation set out in Article 27.3(b) of TRIPS for all World Trade Organization (WTO) members to protect plant varieties through patents, an effective sui generis system, or a combination of systems, heralded revisions to the intellectual property laws and policies on the continent. Africa’s response to Article 27.3(b) of TRIPS was the Organization for African Unity (now African Union—AU) African Model Law for the Protection of the Rights of Local Communities, Farmers, and Breeders, and for the Regulation of Access to Biological Resources (African Model Law), adopted in 2000. Grounded on the dynamic social, economic, and political realities in Africa, the African Model Law seeks to balance small-scale farmers’, farming communities’, and commercial plant breeders’ interests. The African Model Law rejects patents for plant varieties and the wholesale adoption of the 1991 version of the International Convention on the Protection of New Varieties of Plants (UPOV). Instead, it presents a TRIPS-compliant model sui generis option that provides for access and benefit-sharing principles from the Convention on Biological Diversity (CBD), farmers’ rights from the International Undertaking on Plant Genetic Resources for Food and Agriculture (IUPGRFA), and plant breeders’ rights from UPOV 1978 and UPOV 1991. Despite the commendable efforts at creatively designing the Model Law and its historical significance as an African-rooted response to the international debates on the overlapping and conflicting international treaties for plant varieties, the Model Law failed to gain traction in Africa. No African country has adopted it. On the contrary, there is increasing pressure through a coalition of Global North countries, international organizations, and multinational firms for African countries to adopt UPOV-1991-styled plant breeders’ rights systems.

scholarly journals Trends in intellectual property rights protection for medical cannabis and related products

2021 ◽  
Vol 3 (1) ◽  
Author(s):  
Joseph Wyse ◽  
Gilad Luria
Keyword(s):  
Intellectual Property ◽  
Property Rights ◽  
Intellectual Property Rights ◽  
Extraction Methods ◽  
Benefit Sharing ◽  
In Planta ◽  
Medical Cannabis ◽  
Access And Benefit Sharing ◽  
Intellectual Property Rights Protection ◽  
Wide Range

AbstractThe purpose of this review is to advance the field of applied cannabis research by providing insights into the patenting of medical cannabis and current intellectual property rights (IPR) data.Medical cannabis (MC) patent and plant breeders’ rights (PBR) registrations are filed on industrially applicable aspects of research. Studying the filing data and trends informs researchers of both gaps in current applied knowledge in MC (where patents have not been filed) and prior knowledge (where patents have already been filed).Our focus is on those intellectual property rights (IPR) that are registered and germane to technical innovations in MC and related products. These are patents and PBR and thus exclude trade secrets, copyrights, franchises, or trademarks. Methods used for surveying the defined IPR landscape include searches of publicly available patent and PBR data and classifying the data according to the upstream–midstream–downstream innovation paradigm of the MC industry.The findings suggest that the technical knowledge as expressed by patent filings is growing commensurate to the economic and legislative activity. Specific cannabis patents in agricultural technologies directed at improving yield, efficiency, and quality (known as “agritech”) are being filed and granted. These agritech-focused patents represent original novel and applied MC research achievements that address specific problems in cannabis cultivation, such as protection of the cannabis crop, maximizing cannabis yield, harvesting and post-harvesting of cannabis, and new advantageous varieties. Patents on ex planta and in planta cannabis genes expression have been published in recent years while patents on extraction methods for cannabinoids have increased since 2015. Much patent activity is in the downstream category of MC patient-oriented products and delivery systems for a very wide range of medical indications and disease conditions.The emerging importance of access and benefit-sharing treaties and regulations is noted with implications on the industry briefly discussed. Patent data on leading and emerging patentee companies and institutions are shown. We also provide evidence of prior art and freedom to operate.

Sign in / Sign up

Export Citation Format

Share Document